ArticleThe Prostate2020

Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).

Lauren C Harshman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.